Volume : 10, Issue : 12, December – 2023
Title:
EVALUATION OF ANTIDIABETIC ACTIVITY OF LEAVES OF SAMANEA SAMAN ON STREPTOZOTOCIN-INDUCED DIABETES IN RATS
Authors :
Konda Mamatha* , Nagaraju.M.Kulkarni
Abstract :
In India, the number of people suffering from diabetes is believed to be rising steadily and the current antidiabetic therapies are frequently reported to have adverse side effects. Ethno medicinal plant use has shown promise for the development of cheaper, cost-effective antidiabetic agents with fewer side effects. Te aim of this study was to investigate the antidiabetic activity and mechanism of action of Ethanolic extract prepared from Samanea saman. Since this claim has not been investigated scientifically, the aim of this study was to evaluate the antidiabetic effect and phytochemical screening of Streptozotocin -induced diabetic Rats.
The leaves of Samanea saman have been used in traditional health systems to treat diabetes mellitus. However, the antidiabetic activity of this medicinal plant is not scientifically validated and authenticated. The present study aimed to investigate the in vitro and in vivo anti-diabetic activity of flower crude extract and solvent fractions of Samanea saman.
The in vitro α–amylase inhibition of the crude extract and solvent fractions of Samanea saman. Blood glucose lowering activity of 80% Ethanolic crude extract and solvent fraction was studied in animal models: Hypoglycemic rats model, oral glucose loaded rat model, dose-treated Streptozotocin -induced diabetic Rat model. The effect of the crude extract on diabetic lipid profile was studied.
The acute toxicity study of Samanea saman leaves extract did not show mortality in the animals at the limit dose during the observation period. The result of α–amylase enzyme inhibition activity was found in a dose-dependent manner, the strongest activity was shown by Crude extract fraction (89.60 % inhibition at 1000 μg/mL) compared to the standard acarbose having 97.19% inhibition at 1000 μg/mL. The crude extract of Samanea saman showed significant blood glucose-lowering effect on hypoglycemic rats and oral glucose loaded rats. In Streptozotocin -induced diabetic rats model, the crude extract fraction significantly decreased the fasting blood glucose level after 14 days of treatment.
The result demonstrated the beneficial biochemical effects of Samanea saman extract by inhibiting α–amylase improving serum lipid profile levels. The leaves crude extract are effective in lowering blood glucose levels in diabetic and hypoglycemic rats. The claimed traditional use as antidiabetic has scientific ground.
Key words: Diabetes mellitus, Herbal medicine, Samanea saman, Streptozotocin, Anti diabetic activity.
Cite This Article:
Please cite this article in press Konda Mamatha et al, Evaluation Of Antidiabetic Activity Of Leaves Of Samanea Saman On Streptozotocin-Induced Diabetes In Rats, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Consultation, W. H. O. Definition, diagnosis and classification of diabetes mellitus and its complications. Vol. 1. Part, 1999.
2. Alberti, Kurt George Matthew Mayer, and PZ ft Zimmet. “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.” Diabetic medicine 15.7 (1998): 539-553.
3. Gress, Todd W., et al. “Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.” New England Journal of Medicine 342.13 (2000): 905-912.
4. Ahmed, Awad M. “History of diabetes mellitus.” Saudi medical journal 23.4 (2002): 373-378.
5. Zimmet, Paul Z., Daniel J. McCarty, and Maximilian P. de Courten. “The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome.” Journal of Diabetes and its Complications 11.2 (1997): 60-68.
6. American Diabetes Association. “Type 2 diabetes in children and adolescents.”Pediatrics 105.3 (2000): 671-680.
7. Saltiel, Alan R., and C. Ronald Kahn. “Insulin signalling and the regulation of glucose and lipid metabolism.” Nature 414.6865 (2001): 799-806.
8. Browning, Jeffrey D., and Jay D. Horton. “Molecular mediators of hepatic steatosis and liver injury.” Journal of Clinical Investigation 114.2 (2004): 147-152.
9. Aronoff, Stephen L., et al. “Glucose metabolism and regulation: beyond insulin and glucagon.” Diabetes Spectrum 17.3 (2004): 183-190.
10. Ross, E. J., and D. C. Linch. “Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis.” The Lancet320.8299 (1982): 646-649.
11. Levin, Marvin E., Vincenza C. Boisseau, and Louis V. Avioli. “Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes.” New England Journal of Medicine 294.5 (1976): 241-245.
12. Sherwin, Robert, and Philip Felig. “Pathophysiology of diabetes mellitus.” The Medical clinics of North America 62.4 (1978): 695-711.
13. Faber, O. K., and C. Binder. “C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus.” Diabetes 26.7 (1977): 605-610.
14. Ioannidis, Ioannis. “Pathophysiology of Type 1 diabetes.” Diabetes in Clinical Practice: Questions and Answers from Case Studies 31 (2007): 23.
15. Scheen, A. J. “Pathophysiology of type 2 diabetes.” Acta Clinica Belgica 58.6 (2003): 335-341.